NM_004287.5(GOSR2):c.506C>G (p.Ala169Gly) AND Progressive myoclonic epilepsy

Germline classification:: Uncertain significance (1 submission)
Last evaluated:: Feb 10, 2022
Review status:: 1 star out of maximum of 4 stars
criteria provided, single submitter

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV001879116.4

Allele description [Variation Report for NM_004287.5(GOSR2):c.506C>G (p.Ala169Gly)]

NM_004287.5(GOSR2):c.506C>G (p.Ala169Gly)

Genes:

GOSR2:golgi SNAP receptor complex member 2 [Gene - OMIM - HGNC]
LRRC37A2:leucine rich repeat containing 37 member A2 [Gene - OMIM - HGNC]

Variant type:

single nucleotide variant

Cytogenetic location:

17q21.32

Genomic location:

Preferred name:

NM_004287.5(GOSR2):c.506C>G (p.Ala169Gly)

HGVS:

NC_000017.11:g.46938627C>G
NG_031806.2:g.20508C>G
NM_001321133.2:c.506C>G
NM_001321134.2:c.311C>G
NM_001330252.2:c.365C>G
NM_001353114.2:c.503C>G
NM_001353115.2:c.362C>G
NM_001353116.2:c.362C>G
NM_001363851.2:c.452C>G
NM_004287.5:c.506C>GMANE SELECT
NM_054022.4:c.506C>G
NP_001308062.1:p.Ala169Gly
NP_001308063.1:p.Ala104Gly
NP_001317181.1:p.Ala122Gly
NP_001340043.1:p.Ala168Gly
NP_001340044.1:p.Ala121Gly
NP_001340045.1:p.Ala121Gly
NP_001350780.1:p.Ala151Gly
NP_004278.2:p.Ala169Gly
NP_473363.1:p.Ala169Gly
NC_000017.10:g.45015993C>G
NR_148349.2:n.539C>G
NR_148350.2:n.398C>G
NR_148351.2:n.398C>G

Protein change:

A104G

Links:

dbSNP: rs2088814830

NCBI 1000 Genomes Browser:

rs2088814830

Molecular consequence:

NM_001321133.2:c.506C>G - missense variant - [Sequence Ontology: SO:0001583]
NM_001321134.2:c.311C>G - missense variant - [Sequence Ontology: SO:0001583]
NM_001330252.2:c.365C>G - missense variant - [Sequence Ontology: SO:0001583]
NM_001353114.2:c.503C>G - missense variant - [Sequence Ontology: SO:0001583]
NM_001353115.2:c.362C>G - missense variant - [Sequence Ontology: SO:0001583]
NM_001353116.2:c.362C>G - missense variant - [Sequence Ontology: SO:0001583]
NM_001363851.2:c.452C>G - missense variant - [Sequence Ontology: SO:0001583]
NM_004287.5:c.506C>G - missense variant - [Sequence Ontology: SO:0001583]
NM_054022.4:c.506C>G - missense variant - [Sequence Ontology: SO:0001583]
NR_148349.2:n.539C>G - non-coding transcript variant - [Sequence Ontology: SO:0001619]
NR_148350.2:n.398C>G - non-coding transcript variant - [Sequence Ontology: SO:0001619]
NR_148351.2:n.398C>G - non-coding transcript variant - [Sequence Ontology: SO:0001619]

Condition(s)

Name:: Progressive myoclonic epilepsy
Synonyms:: Myoclonic Epilepsies, Progressive; Familial progressive myoclonic epilepsy; Progressive myoclonus epilepsy; See all synonyms [MedGen]
Identifiers:: MONDO: MONDO:0020074; MedGen: C0751778; Orphanet: 308; OMIM: PS254800

Recent activity

Clear Turn Off Turn On

PRNP [Monodelphis domestica]
PRNP [Monodelphis domestica]
Gene ID:554189

Gene

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV002147022	Labcorp Genetics (formerly Invitae), Labcorp	criteria provided, single submitter (Invitae Variant Classification Sherloc (09022015))	Uncertain significance (Feb 10, 2022)	germline	clinical testing	PubMed (1) [See all records that cite this PMID]

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV002147022

Labcorp Genetics (formerly Invitae), Labcorp

criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))

Uncertain significance
(Feb 10, 2022)

germline

clinical testing

PubMed (1)
[See all records that cite this PMID]

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]

PMID:: 28492532
PMCID:: PMC5632818

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV002147022.3

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	PubMed (1)

Description

This sequence change replaces alanine, which is neutral and non-polar, with glycine, which is neutral and non-polar, at codon 169 of the GOSR2 protein (p.Ala169Gly). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with GOSR2-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: Sep 29, 2024

ClinVar

Relating variation to medicine